Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin(SOX)+bevacizumab regimen for advanced colorectal cancer

Trial Profile

Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin(SOX)+bevacizumab regimen for advanced colorectal cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions
  • Acronyms B-Tune study
  • Most Recent Events

    • 13 Oct 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 08 Sep 2017 According to the Trial design presented at the 42nd European Society for Medical Oncology Congress, 21 patients have undergone enrollment at the time of submission of the present abstract
    • 22 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top